LY2245461

LY2245461 is an investigational oral small molecule developed by Chorus, a division of Eli Lilly and Company, for the treatment of menopausal hot flushes (vasomotor symptoms). It was evaluated in a Phase 2 clinical trial to assess its safety, tolerability, and pharmacokinetic profile in healthy postmenopausal women experiencing bothersome hot flushes. The study specifically looked at the effects of multiple oral doses over a 28-day period. Although the specific biological target and mechanism of action have not been publicly disclosed, the compound was part of Eli Lilly's early-stage pipeline for women's health. There is no evidence of recent clinical development, suggesting the program may have been discontinued or remains in early research stages.